PBAC's latest decision on Eptinezumab: Recommended with restriction (2022). Considered for Preventive treatment of chronic migraine in patients with inadequate response, intolerance or contraindication to at least three prior prophylactic migraine therapies.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2022
Submissions
1
2022 → 2022
Eligible population
Adults aged 18 years or older with chronic migraine (≥15 headache days per month with ≥8 migraine days per month for ≥6 months) who have experienced inadequate response, intolerance or contraindication to at least three prophylactic migraine medications.
Therapy area
Neurology
Line of therapy
Later-line
Evidence base
Meta-analysis
Primary endpoint
Reduction in monthly migraine headache days and 50% response rate
Key trials
DELIVER, PROMISE-2, Study 005, CONQUER, REGAIN, FOCUS
Comparator
galcanezumab and fremanezumab
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. Submission presented cost-minimisation approach against galcanezumab.
Risk sharing
Risk-sharing arrangement in place — Special pricing arrangement requested, with effective price to be determined based on cost-minimisation to the effective price of galcanezumab or fremanezumab.